Use of progestogens in pregnant and infertile patients

Abstract

Progesterone is an essential hormone in the occurence and maintenance of pregnancy. Natural or synthetic progestogens are commonly used in pregnant patients or patients undergoing infertility treatments for various indications. Most frequently put indications for the use of progestogens in these patient populations are the prevention of spontaneous preterm birth, the prevention of pregnancy loss in pregnancies with an unexplained recurrent pregnancy loss and in patients with threatened abortion. It is also used in pregnant women undergoing nonobstetric surgery, for infertility or recurrent pregnancy loss that is thought to be due to luteal phase defect or as a luteal support in stimulated IVF cycles. We aimed to review the current evidence for the use of progestogens in each of these settings.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Cunningham FG (ed) (2010) Williams obstetrics, 23rd edn. McGraw-Hill, New York

    Google Scholar 

  2. 2.

    Carey WD (ed) (2009) Cleveland clinic current clinical medicine, 2nd edn. Saunders, Philadelphia

    Google Scholar 

  3. 3.

    Gabbe SG (ed) (2007) Gabbe: obstetrics: normal and problem pregnancies, 5th edn. Churchill Livingstone, Philadelphia

    Google Scholar 

  4. 4.

    Meis PJ, Connors N (2004) Progesterone treatment to prevent pre-term birth. Clin Obstet Gynecol 47:784–795

    PubMed  Article  Google Scholar 

  5. 5.

    Stites DP, Bugbee S, Siiteri PK (1983) Differential action of progesterone and cortisol on lymphocyte and monocyte interaction during lymphocyte activation—relevance to immunosuppression in pregnancy. J Reprod Immunol 5:215–228

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Palagiano A, Bulletti C, Pace MC, De Ziegler D, Cicinelli E, Izzo A (2004) Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann NY Acad Sci 1034:200–210

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Dodd JM, Flenady V, Cincotta R, Crowther CA (2006) Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev 25(1):CD004947

    Google Scholar 

  8. 8.

    Nielsen S, Hahlin M, Platz-Christensen J (1999) Randomised trial comparing expectant with medical management for first trimester miscarriage. Br J Obstet Gynaecol 106:804–807

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Tang OS, Chan CC, Ng EH, Lee SW, Ho PC (2003) A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 18(11):2315–2318

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Majhi P, Bagga R, Kalra J, Sharma M (2009) Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India. J Obstet Gynaecol 29(6):493

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    US Department of Health and Human Services (2011) Food and Drug Administration Statement on Makena.(press release), 30 Mar 2011 US Department of Health and Human Services, Silver Spring

  12. 12.

    Omar MH, Mashita MK, Lim PS, Jamil MA (2005) Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 97(5):421–425 Epub 2005 Nov 15

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Gruber CJ, Huber JC (2005) The role of dydrogesterone in recurrent (habitual) abortion. J Steroid Biochem Mol Biol 97(5):426–430 Epub 2005 Sep 26

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Mattison DR, Damus K, Fiore E, Petrini J, Alter C (2001) Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol 15(Suppl 2):7–16

    PubMed  Article  Google Scholar 

  15. 15.

    Iams JD, Romero R, Culhane JF, Goldenberg RL (2008) Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet 371(9607):164

    PubMed  Article  Google Scholar 

  16. 16.

    Tita AT, Rouse DJ (2009 Mar) Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 200(3):219–224

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Newman RB, Campbell BA, Stramm SL (1990) Objective tocodynamometry identifies labor onset earlier than subjective maternal perception. Obstet Gynecol 76:1089–1092

    PubMed  CAS  Google Scholar 

  18. 18.

    Yemini M, Borestein R, Dreazen E, Apelman Z, Molginer BM, Kessler I et al (1985) Prevention of premature labor by 17 α-hydroxyprogesterone caproate. Am J Obstet Gynecol 151:574–577

    PubMed  CAS  Google Scholar 

  19. 19.

    Dodd JM, Flenady VJ, Cincotta R, Crowther CA (2008) Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol 112(1):127

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Waters TP, Schultz BA, Mercer BM, Catalano PM (2009) Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet Gynecol 114(1):45

    PubMed  CAS  Google Scholar 

  21. 21.

    Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ et al (2007) Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 30(9):2277–2280 Epub 2007 Jun 11

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network., 4 (2009) The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol 201(4):392.e1

    Article  Google Scholar 

  23. 23.

    Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ et al (2007) Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 196(3):224.e1

    Article  Google Scholar 

  24. 24.

    Briery CM, Veillon EW, Klauser CK, Martin RW, Magann EF, Chauhan SP, Morrison JC (2011) Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 204(1):54.e1-5

    PubMed  Article  Google Scholar 

  25. 25.

    Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S et al (2009) Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 373(9680):2034

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Obstetrix Collaborative Research Network (2011) 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 204(3):221.e1

    Article  Google Scholar 

  27. 27.

    PREDICT Group (2011) Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 38(3):272

    Article  Google Scholar 

  28. 28.

    National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (2010) Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-αhydroxyprogesterone caproate. J Matern Fetal Neonatal Med 23(12):1360

    Article  Google Scholar 

  29. 29.

    PREDICT Group (2011) Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 38(3):281

    Article  Google Scholar 

  30. 30.

    National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU) (2009) Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 113(2 Pt 1):285

    Google Scholar 

  31. 31.

    Obstetrix Collaborative Research Network (2010) Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 203(3):248.e1

    Article  Google Scholar 

  32. 32.

    Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462–469

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M (2000) Maternal age and fetal loss: population based register linkage study. Br Med J 320:1708–1712

    Article  CAS  Google Scholar 

  34. 34.

    Wilcox AJ, Weinberg CR, O’Connor JF (1988) Incidence of early loss of pregnancy. N Engl J Med 319:189–194

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Abramson J, Stagnaro-Green A (2001) Thyroid antibodies and fetal loss: an evolving story. Thyroid 11(1):57

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Li TC, Iqbal T, Anstie B, Gillham J, Amer S, Wood K et al (2002) An analysis of the pattern of pregnancy loss in women with recurrent miscarriage. Fertil Steril 78(5):1100–1106

    PubMed  Article  Google Scholar 

  37. 37.

    Haas DM, Ramsey PS (2008) Progestogen for preventing miscarriage. Cochrane Database Syst Rev 16(2):CD003511

    Google Scholar 

  38. 38.

    Coomarasamy A, Truchanowicz EG, Rai R (2011) Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages? BMJ 342:d1914

    PubMed  Article  Google Scholar 

  39. 39.

    Choi BC, Polgar K, Xiao L, Hill JA (2000) Progesterone inhibits in vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 15(Suppl 1):46

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    World Health Organization (1992) International statistical classification of diseases and related health problems, vol 1, 10th edn. World Health Organization, Geneva

    Google Scholar 

  41. 41.

    Wahabi HA, Abed Althagafi NF, Elawad M, Al Zeidan RA (2011) Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 16(3):005943

    Google Scholar 

  42. 42.

    Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B (1987) Doubleblind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol 8:26–34

    PubMed  CAS  Google Scholar 

  43. 43.

    Silver RI, Rodriguez R, Chang TS, Gearhart JP (1999) In vitro fertilization is associated with an increased risk of hypospadias. J Urol 161(6):1954–1957

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Dudas I, Gidai J, Czeizel AE (2006) Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom 46(4):194–198

    Article  CAS  Google Scholar 

  45. 45.

    Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M (1985) Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 65(6):775–780

    PubMed  CAS  Google Scholar 

  46. 46.

    El-Zibdeh MY, Yousef LT (2009) Dydrogesterone support in threatened miscarriage. Maturitas 65(Suppl 1):S43–S46 Epub 2009 Dec 14.

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Pandian RU (2009) Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 65(Suppl 1):S47–S50 Epub 2009 Dec 14

    PubMed  Article  CAS  Google Scholar 

  48. 48.

    Regan L, Rai R (2000) Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 14(5):839

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Balasch J, Fábregues F, Creus M, Vanrell JA (1992) The usefulness of endometrial biopsy for luteal phase evaluation in infertility. Hum Reprod 7(7):973

    PubMed  CAS  Google Scholar 

  50. 50.

    Davis OK, Berkeley AS, Naus GJ, Cholst IN, Freedman KS (1989) The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsies. Fertil Steril 51(4):582

    PubMed  CAS  Google Scholar 

  51. 51.

    Ogasawara M, Kajiura S, Katano K, Aoyama T, Aoki K (1997) Are serum progesterone levels predictive of recurrent miscarriage in future pregnancies? Fertil Steril 68(5):806–809

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Ubaldi F, Bourgain C, Tournaye H, Smitz J, Van Steirteghem A, Devroey P (1997) Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. Fertil Steril 67:521–526

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Macklon NS, Fauser BC (2000) Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil 55(Suppl):101–108

    CAS  Google Scholar 

  54. 54.

    Burney RO, Schust DJ, Yao MWM (2006) Infertility. In: Berek JS (ed) Berek & Novak’s Gynecology. Lippincott Williams & Wilkins, Philadelphia, pp 1185–1275

    Google Scholar 

  55. 55.

    Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 13(6):581–590 Epub 2007 Jul 11

    PubMed  Article  CAS  Google Scholar 

  56. 56.

    Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S (2005) Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 97:416–420

    PubMed  Article  CAS  Google Scholar 

  57. 57.

    Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C (2006) Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 21(10):2572–2579 Epub 2006 Aug 22

    PubMed  Article  CAS  Google Scholar 

  58. 58.

    van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M (2011) Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 5(10):009154

    Google Scholar 

  59. 59.

    Silverberg KM, Vaughn TC, Hansard LJ, Burger NZ, Minter T (2012) Vaginal (Crinone 8 %) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertil Steril 97(2):344–348 Epub 2011 Dec 19

    PubMed  Article  CAS  Google Scholar 

  60. 60.

    Kyrou D, Fatemi HM, Zepiridis L, Riva A, Papanikolaou EG, Tarlatzis BC et al (2011) Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Hum Reprod 26(5):1020

    PubMed  Article  CAS  Google Scholar 

  61. 61.

    Aboulghar MA, Amin YM, Al-Inany HG, Aboulghar MM, Mourad LM, Serour GI, Mansour RT (2008) Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Hum Reprod 23(4):857

    PubMed  Article  Google Scholar 

  62. 62.

    Devroey P, Pados G (1998) Preparation of endometrium for egg donation. Hum Reprod Update. 4(6):856–861

    PubMed  Article  CAS  Google Scholar 

  63. 63.

    Pritts EA, Atwood AK (2002) Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 17(9):2287

    PubMed  Article  CAS  Google Scholar 

  64. 64.

    Bourgain C, Devroey P, Van Waesberghe L, Smitz J, Van Steirteghem AC (1990) Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod 5(5):537

    PubMed  CAS  Google Scholar 

  65. 65.

    Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P (2000) Direct transport of progesterone from vagina to uterus. Obstet Gynecol 95(3):403

    PubMed  Article  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tülay Özlü.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Özlü, T., Güngör, A.Ç., Dönmez, M.E. et al. Use of progestogens in pregnant and infertile patients. Arch Gynecol Obstet 286, 495–503 (2012). https://doi.org/10.1007/s00404-012-2340-4

Download citation

Keywords

  • Abortion
  • Luteal phase
  • Preterm
  • Progesterone
  • Progestogen
  • Short cervix